科研之友
微信
新浪微博
Facebook
分享链接
摘要
Over the past decade we have observed considerable advances in the treatment of autoimmune-mediated disorders affecting the nervous system. Part of this development was the introduction of high-dose polyclonal intravenous immunoglobulins (IVIg). On the basis of randomised, placebo-controlled, double-blind clinical trials, IVIg has become the first line treatment for Guillain-Barre syndrome, chronic idiopathic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN). Furthermore, IVIg can serve as a rescue therapy for patients with rapidly worsening myasthenia gravis, and is a second-line therapy for dermatomyositis, stiff-person syndrome, and pregnancy- or post-partum-associated multiple sclerosis attacks. Due to the excellent safety profile and its uncomplicated administration, IVIg has been used very liberally for most diseases with a suspected autoimmune pathology or where there is no treatment available. This, and the strict licensing requirements, has led to a shortage in IVIg supply and a dramatic increase in costs. Therefore, IVIg should principally be used according to available data from controlled clinical trials. Here we review the clinical applications and recommendations for the use of Wig in neurological diseases.
- 出版日期2007-8
